Patent or proprietary medicine classification and residuary excise recovery upheld where label presentation showed trade connection.

Medicinal preparations may be treated as patent or proprietary medicines for excise purposes where the label, symbol, monogram, or overall style of presentation indicates a trade connection with the manufacturer, even if the product name is taken from the Indian Pharmacopoeia and no registered trade mark is claimed. On limitation, where there was no prior assessment, levy, or nil assessment, the demand was not a short-levy recovery under Rule 10 of the Central Excise Rules, 1944, but fell within the residuary recovery provision under Rule 10A and was not time-barred. The excise demand was therefore sustained and the writ challenge failed.

---

---

Issues: (i) Whether the medicinal preparations were liable to excise duty as patent or proprietary medicines on the basis of the labels, symbol, monogram, and style of presentation used on the containers. (ii) Whether the demand of excise duty was barred by limitation under Rule 10 of the Central Excise Rules, 1944, or fell within Rule 10A.

Issue (i): Whether the medicinal preparations were liable to excise duty as patent or proprietary medicines on the basis of the labels, symbol, monogram, and style of presentation used on the containers.

Analysis: The relevant tariff explanation treated a medicine as patent or proprietary if it bore, on itself or its container, a name or other mark such as a symbol, monogram, label, signature, invented word, or writing used to indicate a connection in the course of trade between the medicine and a person entitled to use that mark. The labels were not confined to a bare statutory statement of the manufacturer's name in ordinary form; they employed calligraphic lettering and a circular device containing the name in a distinctive manner. Even though the medicines carried names from the Indian Pharmacopoeia and no registered trade mark was claimed, the manner of presentation was sufficient to indicate a trade connection with the manufacturer.

Conclusion: The medicines were correctly treated as patent or proprietary medicines and were liable to excise duty; this issue was decided against the petitioner.

Issue (ii): Whether the demand of excise duty was barred by limitation under Rule 10 of the Central Excise Rules, 1944, or fell within Rule 10A.

Analysis: Rule 10 applied only where duty had been short-levied after assessment, or had been paid, adjusted, or nil-assessed earlier. On the facts, there had been no prior assessment, no earlier levy, and no nil assessment in respect of the goods. The demand therefore did not answer the description of a recovery of short levy under Rule 10, but was a claim for duty not covered by any specific provision and so fell within the residuary power under Rule 10A, which carried no time limit.

Conclusion: The demand was not time-barred and was recoverable under Rule 10A; this issue was decided against the petitioner.

Final Conclusion: The challenge to both the classification and limitation grounds failed, so the excise demand was sustained and the writ petition was dismissed.

Ratio Decidendi: A medicine may fall within patent or proprietary medicine if its label or presentation, viewed as a whole, uses a distinctive mark or design that indicates a trade connection with the manufacturer, and where no prior assessment or nil assessment exists, recovery of the duty is governed by the residuary recovery rule rather than the short-levy limitation provision.

---